CME Activity: Type 2 Diabetes and Cardiovascular Disease Risk Management

CME Activity: Approaches to Type 2 Diabetes Management in Patients with Cardiovascular Disease Risk Case Study  (Case Study)



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Knighten Health. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.

The Endocrine Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


  • Upon completion of this educational activity, learners will be able to:
  • Assess unmet needs and treatment patterns of patients with type 2 diabetes not at target
  • Discuss benefits and limitations of currently approved type 2 diabetes drug classes for patients with or at risk of cardiovascular disease
  • Assess and select appropriate diabetes agents to help patients with or at risk of cardiovascular disease get to goal
  • Understand how to integrate approved type 2 diabetes drug classes into treatment plans based on patient medical characteristics, personal preferences, and glycemic goals

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, family physicians, general practitioners and healthcare professionals who treat patients with diabetes.

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following faculty reported relevant financial relationships:
Doron Schneider, MD: Consultant, Janssen Pharmaceuticals, Inc., Lilly USA, LLC, Novo Nordisk Inc.

Bernard Zinman, MD: Consultant, Merck, Novo Nordisk Inc., Sanofi-Aventis, Eli Lilly, AstraZeneca, Janssen Pharmaceuticals, Inc., and Boehringer Ingelheim, and grant support to his institution from Merck, Novo Nordisk, and Boehringer Ingelheim

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

This activity is supported by an educational grant from Novo Nordisk, Inc.

This enduring material is presented in an online format. The estimated time to complete this activity, including review of material, is 0.5 hours. To receive a maximum of 0.5 AMA PRA Category 1 Credits™ participants must complete an activity evaluation, as well as a posttest achieving a minimum score of 65%. If learners do not achieve a passing score of 65%, they have the option to retake the post-test.

To claim your CME credit, please follow these steps:

  1. Carefully review all the information about the CME credit prior to viewing the content.

  2. Read the activity in its entirety.

  3. Select the link to complete the posttest and evaluation.

  4. You must receive a passing score of 65% on the posttest and answer all the evaluation questions in order to earn credit from the activity. You may retake the posttest as many times as necessary in order to pass.

  5. After successful completion of the online test and evaluation, you will be given the opportunity to download a personalized CME certificate for participation in this activity.

LAST REVIEW DATE: February 15, 2017
ACTIVITY RELEASE DATE: February 15, 2017
ACTIVITY EXPIRATION DATE: February 15, 2018 (date after which this enduring material is no longer certified for AMA PRA Category 1 Credits™)

For technical assistance or information, please contact Knighten Health.

For questions about content or obtaining CME credit, please contact the Endocrine Society at